PM Modi visits Bharat Biotech's vaccine manufacturing facility in Hyderabad

Covaxin, being developed by Bharat Biotech in collaboration with the
Indian Council of Medical Research and National Institute of Virology,
is now undergoing phase-3 trials. The Phase-3 trials involve 26,000
volunteers across India, conducted in partnership with ICMR.

https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/pm-modi-visits-bharat-biotechs-vaccine-manufacturing-facility-in-hyderabad/articleshow/79462953.cms

Comments

Popular posts from this blog

Biotecnika Times Newsletter 25.10.2021 Tata Innovation Fellowship 2021, NCCS PhD Admission

TIGS-CI Biological Sciences Research Assistant Recruitment, Apply Online